The Minister for Jobs, Enterprise and
Innovation, Richard Bruton TD today made an an announcement on a $37.5m
investment under the Innovation Fund Ireland programme in Sofinnova Ventures.
Sofinnova Ventures is said to be "one of the premier US healthcare venture
capital funds, recently raising their eighth fund, a $440M vehicle focused
solely on life sciences," and the fund will be establishing a presence in
the Irish Market. Enterprise Ireland has committed $25 million to the Fund,
alongside a commitment of $12.5 million by the National Pensions Reserve Fund.
It appears that the US venture capital firm is
being paid to open an office in Dublin.
Making the announcement in Bruton said: “Developing a dynamic venture
capital industry in Ireland is a key part of this Government’s growth strategy.
Venture capital funds provide crucial funding, as well as mentoring and advice,
to early-stage high-potential companies in key high-growth sectors. That is why
the Programme for Government outlines the Government’s determination to support
the development of a more dynamic venture capital industry in Ireland by seeking
to attract top tier venture capitalists to invest in Ireland, and why the Action
Plan for Jobs commits to delivering a number of key measures to step up our
performance in this area”.
“Healthcare and life sciences is a sector which the Government has identified as
having potential for high levels of employment growth, and today's announcement
will mean that more high-growth Irish companies can meet this leading life
"I am determined that, with implementation of good Government policies, we will
see further development of a dynamic venture capital industry in Ireland. In
this way, high-growth Irish companies will have access to the funding they need
and we can help achieve the levels of growth we so badly need".
"I look forward to welcoming the Sofinnova team to Ireland and connecting them
with the best life sciences companies in Ireland.”
Mike Powell, General Partner of Sofinnova said, “We are
pleased to welcome Enterprise Ireland and the National Pensions Reserve Board as
Limited Partners to our next fund, and they nicely complement the global and
strong investor base we have in Sofinnova Ventures VIII. Ireland has produced
several outstanding life science companies, including the Sofinnova portfolio
company, Amarin Corporation. We look forward to continuing to build industry
leading companies for our investors.”
Check out our new
subscription service, Finfacts Premium
, at a low annual charge of €25 - - if
you are a regular user of Finfacts, 50 euro cent a week is hardly a huge ask to
support the service.
It's a simple fact that in the
prevailing economic climate, the provision of high quality content cannot be
sustained through advertising alone.
Business executives who put a
premium on time and value high quality information, should use our service.
Execute access is denied.